Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
7
×
boston top stories
life sciences
national blog main
national top stories
startups
7
×
biotech
new york blog main
new york top stories
san francisco blog main
deals
san francisco top stories
boston
clinical trials
vc
biogen
cancer
drug discovery
glaxosmithkline
investing
ipo
ptc therapeutics
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
third rock ventures
venture capital
accent therapeutics
acetylon pharmaceuticals
aducanumab
allosteric
alnylam pharmaceuticals
alzheimer's disease
amblyotech
ambys medicines
antisense oligonucleotide
asklepios biopharmaceutical
atlas venture
atopic dermatitis
What
medicines
7
×
new
7
×
adds
aims
biotech
developing
disease
drugs
research
startup
therapeutics
activity
address
ago
aim
aiming
alliance
allosteric
ambys
approach
approvals
areas
backed
based
big
bio
biogen
biosciences
bio’s
boost
brii
called
cancer
cause
ceo
change
clamped
clinic
community
control
Language
unset
Current search:
new
×
startups
×
photo
×
medicines
×
" boston blog main "
×
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?